AVEO Pharmaceuticals Revenue 2010-2022 | AVEO
AVEO Pharmaceuticals revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
AVEO Pharmaceuticals Annual Revenue
(Millions of US $) |
| 2021 |
$42 |
| 2020 |
$6 |
| 2019 |
$29 |
| 2018 |
$5 |
| 2017 |
$8 |
| 2016 |
$3 |
| 2015 |
$19 |
| 2014 |
$18 |
| 2013 |
$1 |
| 2012 |
$19 |
| 2011 |
$165 |
| 2010 |
$45 |
| 2009 |
$21 |
AVEO Pharmaceuticals Quarterly Revenue
(Millions of US $) |
| 2022-03-31 |
$21 |
| 2021-12-31 |
$18 |
| 2021-09-30 |
$15 |
| 2021-06-30 |
$8 |
| 2021-03-31 |
$2 |
| 2020-12-31 |
$1 |
| 2020-09-30 |
$4 |
| 2020-06-30 |
$1 |
| 2020-03-31 |
$1 |
| 2019-12-31 |
$1 |
| 2019-09-30 |
$26 |
| 2019-06-30 |
$1 |
| 2019-03-31 |
$2 |
| 2018-12-31 |
$1 |
| 2018-09-30 |
$2 |
| 2018-06-30 |
$0 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$0 |
| 2017-09-30 |
$5 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$3 |
| 2016-12-31 |
$0 |
| 2016-09-30 |
$1 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
$1 |
| 2015-12-31 |
$4 |
| 2015-09-30 |
$15 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$1 |
| 2014-06-30 |
$2 |
| 2014-03-31 |
$15 |
| 2013-12-31 |
$0 |
| 2013-09-30 |
$0 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
$16 |
| 2012-09-30 |
$1 |
| 2012-06-30 |
$2 |
| 2012-03-31 |
$1 |
| 2011-12-31 |
$1 |
| 2011-09-30 |
$4 |
| 2011-06-30 |
$27 |
| 2011-03-31 |
$134 |
| 2010-12-31 |
$12 |
| 2010-09-30 |
$6 |
| 2010-06-30 |
$16 |
| 2010-03-31 |
$11 |
| 2009-12-31 |
$6 |
| 2009-09-30 |
$6 |
| 2009-06-30 |
$5 |
| 2009-03-31 |
$4 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.146B |
$0.042B |
|
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
|
